Back to search results

Comparing Dexcom CGM to Standard Glucose Testing for Type 1 Diabetes in the Hospital

This study is comparing two ways to monitor blood sugar in people with Type 1 Diabetes while they are in the hospital and shortly after they go home. It's looking at the Dexcom G7 Continuous Glucose Monitoring (CGM) system, which continuously measures sugar levels, versus the usual Point of Care (POC) blood glucose testing, which uses finger pricks. The main goal is to see if one method is better at keeping blood sugar levels within a healthy range (70-180 mg/dl) and preventing dangerously low blood sugar (hypoglycemia, below 54 mg/dl). You can join if you are 18 or older and have Type 1 Diabetes treated with insulin. The study aims to enroll 100 participants, but its current recruitment status is unclear.

Study design
This interventional study plans to enroll 100 participants with Type 1 Diabetes. It compares two different methods for monitoring blood sugar.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, which is Day 10 or the length of their hospital admission.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06752928

A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes

Recruiting
NAAges 18+InterventionalPrevention
Emory University
~100 participants
Updated 2025-10-08 on ClinicalTrials.gov
What's tested:Dexcom G7 rtCGMCapillary Blood glucose Testing (POC)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Glycemic control
Measured over Through study completion (Day 10 or the length of admission)
+1 more outcome measured

Conditions

Type 1 Diabetes

Explore related trials

Type 1 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Guillermo Umpierrez, MD · PRINCIPAL_INVESTIGATOR · Emory University

Who to contact

Guillermo Umpierrez, MD
[email protected]
404-778-1665
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Known history of T1D treated with insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs \[lispro, aspart, glulisine, fast-acting insulin aspart, insulin lispro\]), intermediate-acting (NPH and premixed formulations) or long-acting basal (glargine, detemir, degludec) formulations.
Admission diagnosis of T1D with poorly controlled diabetes (blood glucose \> 180 mg/dl, HbA1c \> 7%), including diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS).
Expected length of hospital stay \> three days at the time of randomization

Exclusion

Patients admitted to the ICU
Subjects using CGM technology before admission
Subjects with type 2 diabetes
Treatment with systemic immunosuppressive agents
Cystic fibrosis
Prisoners
Patients expected to require MRI procedures during hospitalization.
Female subjects who are pregnant or breastfeeding at enrollment into the study.
Subjects not willing to wear a CGM device
Subjects with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension) and end-stage kidney disease (eGFR\< 30 ml/min), or terminal illness.
Subjects with a history of cognitive impairment, dementia, or mental condition rendering the subject unable to understand the nature and consequences of the study

What this trial measures

  • Glycemic controlThrough study completion (Day 10 or the length of admission)

    The total difference in blood sugar levels between the POC testing (standard of care) group and the rtCGM group throughout the hospitalization

  • Clinically significant hypoglycemia <54 mg/dlThrough study completion (Day 10 or the length of admission)

    The difference between blood sugar levels in POC testing (standard of care) group and rtCGM group during hospitalization